Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Artigo em Inglês | MEDLINE | ID: mdl-33495229

RESUMO

OPS-2071 is a novel quinolone antibacterial agent characterized by low oral absorption that reduces the risk of adverse events typical of fluoroquinolone class antibiotics. The in vitro and in vivo antibacterial activities of OPS-2071 against Clostridioides difficile were evaluated in comparison to vancomycin and fidaxomicin. OPS-2071 exhibited potent antibacterial activity against 54 clinically isolated C. difficile strains with a MIC of 0.125 µg/ml (MIC50) and 0.5 µg/ml (MIC90), making it more active than vancomycin on a concentration basis (MIC50, 2 µg/ml; MIC90, 4 µg/ml) and comparable to fidaxomicin (MIC50, 0.063 µg/ml; MIC90, 8 µg/ml). OPS-2071 showed equally potent antibacterial activity against both hypervirulent and nonhypervirulent strains, while a significant difference in susceptibility to fidaxomicin was observed. Spontaneous resistance to OPS-2071 and vancomycin was not observed; however, resistance to fidaxomicin was observed at 4× MIC. The mutant prevention concentration of OPS-2071 was 16-fold lower than those of fidaxomicin and vancomycin, and the postantibiotic effect of OPS-2071 was longer than those of fidaxomicin and vancomycin. Also, OPS-2071 showed low systemic exposure, with OPS-2071 having 2.9% oral bioavailability at 1 mg/kg in rats. Furthermore, OPS-2071 showed significant in vivo efficacy at 0.0313 mg/kg/day (50% effective doses), 39.0-fold and 52.1-fold lower than those of vancomycin and fidaxomicin, respectively, in a hamster model of C. difficile infection. OPS-2071 has the potential to become a new therapeutic option for treating C. difficile infection.


Assuntos
Clostridioides difficile , Infecções por Clostridium , Quinolonas , Aminoglicosídeos/farmacologia , Animais , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Clostridioides , Infecções por Clostridium/tratamento farmacológico , Testes de Sensibilidade Microbiana , Ratos
3.
J Org Chem ; 72(9): 3218-22, 2007 Apr 27.
Artigo em Inglês | MEDLINE | ID: mdl-17408285

RESUMO

The palladium-catalyzed cyclocarbonylation reaction of o-iodoanilines with allenes and CO in 1-butyl-3-methylimidazolium hexafluorophosphate afforded 3-methylene-2,3-dihydro-1H-quinolin-4-ones in moderate to excellent yields under a low pressure (5 atm) of CO. The ionic liquid, as the solvent and promoter, enhances the efficiency of the cyclocarbonylation reaction. The recyclability of the system of ionic liquid/catalyst/ligand was also demonstrated.


Assuntos
Compostos de Anilina/química , Química Orgânica/métodos , Paládio/química , Quinolinas/química , Alcadienos/química , Catálise , Líquidos Iônicos/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA